>>US FDA panel rejects Abbott prostate cancer drug Tue Sep 13, 2005 12:00 PM ET
BETHESDA, Md., Sept 13 (Reuters) - Abbott Laboratories Inc.'s (ABT.N: Quote, Profile, Research) experimental drug Xinlay should not be approved for treating men with advanced prostate cancer, a U.S. advisory panel unanimously said on Tuesday.
The Food and Drug Administration will make the final decision, but the agency usually follows recommendations from advisory panels.<<
Market Data 
Markets 
AI
